BiotechTube
NovalGen

NovalGen

London, United Kingdom· Est.
novalgen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.5M

Overview

NovalGen is an innovative UK-based biotech advancing a pipeline of multi-specific biologics powered by its novel AutoRegulation platform, designed to enhance safety and efficacy. The company is in the clinical stage, having initiated its first Phase 1 trial for a T-cell engager in 2026 and planning the world's first trial for a self-regulating immunotherapy. With strong academic roots from UCL and strategic partnerships, NovalGen is targeting significant unmet needs across immunology and oncology.

OncologyAutoimmuneHaematologicalMetabolic

Technology Platform

Proprietary AutoRegulation (AR) platform designed to engineer self-regulating capabilities into multi-specific biologics, aiming to enhance safety and therapeutic efficacy by creating context-aware therapies.

Funding History

2
Total raised:$18.5M
Series A$15M
Seed$3.5M

Opportunities

The AutoRegulation platform addresses a major limitation in immunotherapy—uncontrolled toxicity—potentially enabling safer, more effective treatments for solid tumors and autoimmune diseases.
The growing multi-billion dollar market for bispecific and conditionally active therapies offers a significant commercial opportunity for validated technology.

Risk Factors

High technical risk associated with the novel and unproven AutoRegulation platform in human trials.
Clinical development risk in demonstrating both safety and efficacy in Phase 1 studies, coupled with intense competition from larger biopharma companies in the multi-specific antibody space.

Competitive Landscape

NovalGen competes in the crowded and rapidly evolving field of multi-specific antibodies and engineered immunotherapies. It faces competition from large biopharma (e.g., Roche, Amgen, Sanofi) and numerous biotechs. Its differentiation hinges on the success of its AutoRegulation platform to offer a superior safety profile versus standard T-cell engagers and other immunomodulators.

More companies in Immunotherapy / Immuno-Oncology →More companies in United Kingdom →